I always thought Nolva competed with estrogen at all receptor sites being that its an estrogen agonist.
It may do this better with breast tissue but it would compete with all estrogen at all the receptors.
Associate Member
I always thought Nolva competed with estrogen at all receptor sites being that its an estrogen agonist.
It may do this better with breast tissue but it would compete with all estrogen at all the receptors.
Associate Member
I'm interested if its true that a estrogen agonist can selectively target only BREAST estrogen receptors.
Does anyone have any documentation/studies supporting this?
There are currently 1 users browsing this thread. (0 members and 1 guests)
Posting Permissions
Reply With Quote